NCT02569203

Brief Summary

To determine whether high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients (eg, ω-3 fatty acids and antioxidants) enriched with β-glucan stimulates immune functions compared with standard enteral nutrition (control: 20% of total calorie from protein) or high-protein (24% of total calorie from protein) enteral nutrition of immune modulating nutrients without β-glucan in critically ill patients.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2014

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

September 24, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 6, 2015

Completed
Last Updated

October 6, 2015

Status Verified

October 1, 2015

Enrollment Period

1.4 years

First QC Date

September 24, 2015

Last Update Submit

October 5, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline NK cell activity at 7 days

    NK cell activity (%)

    at baseline and 7 days follow-up

Secondary Outcomes (2)

  • Change from baseline IL-12 at 7 days

    at baseline and 7 days follow-up

  • Change from baseline hs-CRP at 7 days

    at baseline and 7 days follow-up

Study Arms (3)

control group

PLACEBO COMPARATOR

standard enteral nutrition

Dietary Supplement: standard enteral nutrition

test group I

EXPERIMENTAL

high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan

Dietary Supplement: high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan

test group II

EXPERIMENTAL

high-protein enteral nutrition of immune modulating nutrients without β-glucan

Dietary Supplement: high-protein enteral nutrition of immune modulating nutrients without β-glucan

Interventions

standard enteral nutritionDIETARY_SUPPLEMENT

standard enteral nutrition

Also known as: control group
control group

high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan

Also known as: test group I
test group I

high-protein enteral nutrition of immune modulating nutrients without β-glucan

Also known as: test group II
test group II

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • ICU patients

You may not qualify if:

  • ICU patients who could not receiving enteral nutrition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Lee JG, Kim YS, Lee YJ, Ahn HY, Kim M, Kim M, Cho MJ, Cho Y, Lee JH. Effect of Immune-Enhancing Enteral Nutrition Enriched with or without Beta-Glucan on Immunomodulation in Critically Ill Patients. Nutrients. 2016 Jun 2;8(6):336. doi: 10.3390/nu8060336.

MeSH Terms

Conditions

Critical Illness

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Jong Ho Lee, Ph. D.

    Dept. of Food and Nutrition, College of Human Ecology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, South Korea

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2015

First Posted

October 6, 2015

Study Start

April 1, 2014

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

October 6, 2015

Record last verified: 2015-10